These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 1622128

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
    Kobayashi H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
    [Abstract] [Full Text] [Related]

  • 24. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K, Bian M, Zhu D, Liu W, Siu S.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [Abstract] [Full Text] [Related]

  • 25. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L, Cui H, Li XP, Sun LF, Chang XH, Liang XD, Zhu HL.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [Abstract] [Full Text] [Related]

  • 26. [Tumor marker in ovarian cancer].
    Komai K, Nishida T.
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U, Johannsen B, Elling D.
    Zentralbl Gynakol; 1989 Mar; 111(5):301-9. PubMed ID: 2728673
    [Abstract] [Full Text] [Related]

  • 31. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J, Qian H, Tian Y.
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [Abstract] [Full Text] [Related]

  • 32. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY.
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [Abstract] [Full Text] [Related]

  • 33. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Overview of potential oncomarkers for detection of early stages of ovarian cancer].
    Urban P, Bilecová-Rabajdová M, Stefeková Z, Ostró A, Mareková M.
    Klin Onkol; 2011 Feb; 24(2):106-11. PubMed ID: 21644365
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.